Physician profile
Steven H Lee
NPI 1568439206
$2,646.79
in general payments reported to CMS, 2019-2025
26 companies · $476 in 2025
The $476 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $248 · 2021: $318 · 2022: $455 · 2023: $307 · 2024: $369 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,052 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,052.36 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $658.57 | 2019-2023 | |
| Astellas Pharma US INC | $503.24 | 2019-2025 | Veozah |
| Daiichi Sankyo INC. | $257.47 | 2019-2023 | Injectafer |
| Evofem Biosciences, INC. | $203.59 | 2020-2025 | Phexxi, Solosec, Phexx |
| Bayer Healthcare Pharmaceuticals INC. | $108.46 | 2019-2025 | |
| Dysis Medical, INC. | $98.79 | 2020-2022 | |
| Exeltis, USA INC. | $91.18 | 2020-2025 | Slynd |
| Meditrina | $86.85 | 2022-2024 | |
| Biogen, INC. | $80.95 | 2024-2025 | Zurzuvae |
| Duchesnay USA Incorporated | $72.88 | 2019 | |
| Hologic Sales and Service, LLC | $56.75 | 2022-2023 | Aptima |
| Shield Therapeutics INC | $56.34 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $51.29 | 2024 | |
| Lupin INC. | $48.83 | 2019 | |
| Optumhealth Care Solutions, LLC | $35.33 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $34.89 | 2022-2024 | |
| Organon LLC | $32.59 | 2022-2023 | Nexplanon |
| Alkermes, INC. | $24.39 | 2021 | |
| Aspira Women'S Health INC | $24.35 | 2019 | |
| Mylan Pharmaceuticals INC. | $20.47 | 2021 | |
| Coopersurgical, INC. | $20.17 | 2025 | Paragard T 380a |
| Therapeuticsmd, INC. | $17.77 | 2019 | |
| Baxter Healthcare | $16.99 | 2022 | |
| Acessa Health INC. | $15.90 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.11 | 2025 | Uzedy |
| Allergan, INC. | $13.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.